Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer

Core Insights - Provectus Biopharmaceuticals announced the publication of preclinical research on PV-10 for head and neck squamous cell carcinoma (HNSCC) [1][2] - The study reveals novel mechanistic findings that could support future clinical development of PV-10 in locally recurrent HNSCC [2] - PV-10 is an investigational cancer immunotherapy derived from pharmaceutical-grade rose bengal sodium [3] Group 1: Research and Development - The research conducted by the Chung Lab at Moffitt Cancer Center demonstrates PV-10's ability to induce immunogenic cell death in HNSCC through endoplasmic reticulum stress and apoptosis [2][4] - Provectus plans to initiate a Phase 1 trial of intratumoral PV-10 in pre-operative penile squamous cell carcinoma later this year [4] Group 2: Company Overview - Provectus is a clinical-stage biotechnology company focused on developing immunotherapy medicines based on synthetic small molecules known as halogenated xanthenes [5] - The company's lead molecule is Rose Bengal Sodium, which is central to its medical science platform that includes oncology, dermatology, and ophthalmology programs [6] Group 3: Clinical Trials and Information - Information regarding Provectus's clinical trials can be accessed through the National Institutes of Health registry, ClinicalTrials.gov [7]